Journal
ONCOIMMUNOLOGY
Volume 4, Issue 1, Pages -Publisher
LANDES BIOSCIENCE
DOI: 10.4161/2162402X.2014.983770
Keywords
cancer vaccine; CD8; IDO; NSCLC; PD-L1
Categories
Funding
- The Danish Cancer Society [R72-A4460] Funding Source: researchfish
Ask authors/readers for more resources
Indoleamine 2,3-dioxygenase (IDO) is an immunoregulatory enzyme. Remarkably, we discovered IDO-specific T cells that can influence adaptive immune reactions in patients with cancer. Further, a recent phase I clinical trial demonstrated long-lasting disease stabilization without toxicity in patients with non-small-cell lung cancer (NSCLC) who were vaccinated with an IDO-derived HLA-A2-restricted epitope.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available
Share Paper
